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SUMMARY 
The carcinogenic potential of  tilidine fumarate, a synthetic analgesic, was 
studied for 80 and 104 weeks in mice and rats, respectively. Groups of  50 
albino CF1 mice and 65 albino Wistar rats of  each sex received tilidine 
fumarate-lactose blend (1 : 1) at doses of  100, 40 and 16 mg/kg. The control  
groups consisted of  100 mice and 115 rats of each sex and received the 
lactose vehicle only. Treatment-related non-neoplastic changes corisisted of  
reversible, increased cytoplasmic eosinophilia of  hepatocytes  in high and mid 
dose rats corresponding to areas of  proliferating smooth endoplasmic 
reticulum; and an increased incidence in high dose rats of  proliferative or 
cystic lesions of  the biliary epithelium. Adequate  survival rates allowed 
stringent statistical analysis of neoplasia. Tilidine did not  evoke increased 
tumor  incidences or changes in the average latency or onset  of  tumors in 
either species. The most  frequent  tumors represented spontaneous neoplasia 
characteristic of  historical background incidence in these strains. In mice, the 
only statistically significant (P < 0.01) variation in tumor  incidence was an 
increased rate of  lung alveologenic adenocarcinomas in females at 100 mg/kg 
(24%), compared with the concurrent untreated controls {10%), but  wi thout  
a statistically significant difference from historical control data (27%). Female 
rats given 100 mg/kg showed statistically significant (P < 0.01) decreased 
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incidences of mammary fibroadenoma and pituitary adenoma. From these 
data, it was concluded that the synthetic analgesic tilidine does not possess 
tumorigenic potential in rodents. 
Key words: Carcinogenesis; Chronic toxicity; Synthetic analgesic; Tilidine 
(Valoron) 
INTRODUCTION 
The substituted cyclohexenylamine tilidine (Valoron) was synthesized by 
Satzinger [1]. The pharmacology profile indicated analgesic properties [2]. 
Later, pharmacokinetic studies [3,4], animal toxicology [5,6], metabolism 
[7--9], initial clinical investigations [10], and the analytical profile [11] 
were reported. The pharmacological, epidemiological and clinical aspects 
of tilidine dependence and abuse have been reviewed [12]. The activity 
profile of tilidine remains controversial with respect to the involvement of 
opiate receptors [13,14]. 
The animal experiments reported herein were undertaken to evaluate the 
carcinogenic potential of tilidine in rats and mice. There are minimal pub- 
lished data available on the long-term toxicity or carcinogenicity of substi- 
tuted cyclohexenylamines with potent analgesic activity. A preliminary 
report was available earlier [15]. 
MATERIALS AND METHODS 
Chemical 
Tilidine (Fig. 1), a substituted cyclohexenylamine, trans-(+)-2-{dimethyl- 
amino)-l-phenyl-3-cyclohexene-l-carboxylic acid ethyl ester, has a molecular 
formula of C,TH23NO2 and a molecular weight of 273.4. The fumarate salt 
of tilidine in a lactose blend (1:1) was used in the conduct of these studies, 
and throughout this paper dose levels are expressed in terms of this formu- 
lation. 
Animals and housing. 
Random bred, barrier raised albino CF, mice and albino Wistar rats were 
supplied by Carworth Farms, New City, NY, and Hilltop Laboratory Animals, 
CH 3 
Fig. 1. Tilidine: trans-(*--)-2-(dimethylamino)-l-phenyl-3-eyelohexene-l-earboxylie acid 
ethyl ester. 
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Inc., Scottdale, PA, respectively. These animal strains were selected for these 
experimental studies because of  historical data accumulated in this laboratory 
since the inception of the in-house carcinogenesis bioassay program in 1967. 
These strains have adequate survival rates at 80 weeks for mice and 104 weeks 
for rats, and historically have shown a moderate  incidence of  spontaneous 
neoplasia, and a low incidence of  intercurrent pathology. 
Clinically substandard animals were culled during a 2-week quarantine 
period and the remaining animals were assigned randomly to experimental 
groups to provide comparable mean body weights at s tudy initiation. Animals 
assigned were approximately 42 days old at s tudy initiation. Rats were 
housed individually in suspended stainless-steel cages while mice were 
housed in groups of 3 in plastic boxes with pressed hardwood bedding 
chips. Some male mice were subsequently separated into individual units as 
a result of  aggressive behavior. The animals were maintained in clean rooms 
with controlled temperature (23 + 2°C) and relative humidi ty (40--60%). 
Each room had 18 fresh air exchanges per hour and was maintained on an 
11-h photoperiod.  The species were housed in separate animal rooms. Fresh 
water was supplied ad libitum and animals were offered standard laboratory 
ration (Purina Lab Chow). 
Experimental groups 
Dose levels selected for these experiments were based upon an overall 
assessment of effects in previous acute, subchronic and long-term toxicology 
studies. Briefly, tilidine hydrochloride was tested in rats, orally at doses of 
25, 50 and 100 mg/kg for 6 months [5] .  Central nervous system excitation 
was observed in rats given 100 mg/kg orally. Histologic examination of  these 
high dose animals revealed cloudy swelling and fa t ty  change of  centrilobular 
hepatocytes.  These reversible liver changes were slight in rats given 50 mg/kg. 
Based upon these data, the maximum tolerated dose was estimated to be 
100 mg/kg. Tilidine fumarate, at a dose of 100 mg/kg administered as a 
dietary admixture for 8 weeks, was well tolerated. Food  consumption was 
slightly reduced and the only clinical sign observed was abdominal fur loss. 
Therefore, groups of  50 mice and 65 rats of each sex received tilidine 
fumarate-lactose blend (1 :1)  at 100, 40 and 16 mg/kg/day. The untreated 
control  groups consisted of 100 mice and 115 rats of  each sex. 
Experimental procedures 
Animals were weighed once weekly for the initial 6 months of  study and 
biweekly thereafter. Food  consumption was measured weekly throughout  
the entire experimental period. Drug levels in diet were adjusted weekly to 
compensate for changes in mean body  weight and food consumption.  
All animals were observed daily for evidence of  overt toxic reactions. 
Physical examinations were performed pretest and at monthly  intervals. 
Ophthalmic examinations were performed on all mice at monthly  intervals 
and in rats pretest and at 6-month intervals. Clinical laboratory studies were 
conducted on 5 rats/sex group sacrificed at 6, 12 and 18 months,  and on at 
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least 10 animals/sex group sacrificed at termination (24 months). Serum 
analyses included fasting blood glucose (ferrocyanide oxidation), blood urea 
nitrogen (BUN: diacetyl monoxime reaction), alkaline phosphatase (p- 
phenyl phosphate hydrolysis) and glutamate pyruvate transaminase (GPT: 
dinitrophenylhydrazine reaction). All tests were conducted by Auto-Analyzer 
with commercially available kits and reagents. Hematologic examinations 
included hemoglobin (Coulter Hemoglobinometer), hematocrit (Clay-Adams 
Autocrit), total red blood cells and total white blood cells (Coulter Counter). 
Platelets were counted manually in a Neubauer counting chamber. Analyses 
on urine included specific gravity (American Optical T.S. Meter), bilirubin 
{Ames Icotest), and occult blood, ketones, glucose, protein, and bilirubin 
(Ames Labstix). Five rats per sex group were withdrawn from compound 
administration after 88 weeks of dosing and were maintained on study to 
104 weeks to evaluate the reversibility of liver changes [6]. 
Pathology studies 
Moribund animals were sacrificed for humane reasons and to minimize 
onset of autolytic changes in the event of death. All animals were autopsied; 
those sacrificed in extremis were considered deaths for the purposes of data 
analysis. For animals sacrificed at termination, organ weights and organ to 
body weight ratios were determined for gonads, liver, kidneys, prostate, and 
uterus. In rats, thyroid and adrenal weights also were determined. After gross 
pathologic examinations, tissues and gross abnormalities from all animals 
were processed and evaluated microscopically. 
Methods o f  statistical analysis 
All tumors noted during gross pathologic examination were processed for 
microscopic evaluation. The time of onset of all microscopically characterized 
tumors was set when they were first noted during clinical examination in 
the in vivo phase. The onset of internal, non-palpable tumors was established 
as the date of autopsy. The methodology for analyzing the tumor incidences 
followed a modified life-table technique [16]. The criteria for tumorigenic 
response were based on histotyping of tumors, dose relationships, statistically 
significant differences in tumor frequency (P < 0.01), changes in onset, 
average latency, and the occurrence of highly unusual or unexpected tumors. 
For non-tumor data (i.e., clinical laboratory parameters and organ weights 
and ratios), pair-wise comparison of each treated group to untreated controls 
was made by analysis of variance and the Student's t-test [17]. 
R E S U L T S  
Survival data of animals fed the various drug regimens are shown in Figs. 
2 and 3 for mice and rats, respectively. Group survival rates in both mice 
(29--72%) and rats (46--58%) ensured adequate statistical power for tumor 
analysis. Mice died mainly as a result of routine leukemia or, in the case of 
males, obstructive uropathy as a result of aggressive behavior and mutilation. 
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Upon gross examination, animals later confirmed microscopically to have 
murine leukemia, generally had marked enlargement of lymph nodes, thymus 
and spleen. The thymus and lymph nodes were soft with a homogeneous pale 
tan color, while the spleen was dark red, firm and occasionally focally 
necrotic. Surviving animals remained in satisfactory clinical condition 
throughout the studies. Clinical signs and ophthalmic lesions were related 
to aging changes in both species. There was significant dose-related body 
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weight gain suppression during the final year of  study in rats given 100 and 
40 mg/kg. Body weight gain suppression in males and females given doses of  
100, 40 and 16 mg/kg was 26%, 14% and 6%, and 23%, 6% and 4%, respec- 
tively. Rats removed from treatment  after 88 weeks did not  show significant 
weight gain during the withdrawal period. Only minor variations in food 
consumption occurred in both  species. In rats, no significant differences 
were observed in biochemical, hematological and urinalysis parameters of  
treated and control  groups. Selected parameters from those evaluated, and 
relevant to liver and kidney function, are summarized in Table I. 
Dose-related increases in absolute liver weights and ratios were observed 
in treated male and female rats surviving to study termination (Table II). 
Absolute liver weights and ratios were comparable to control values in animals 
given drug for 88 weeks fol lowed by 16 weeks of  withdrawal. Other 
variations in absolute organ weights and associated ratios, in both rats and 
mice, were related to either body  weight gain suppression or were considered 
incidental, and could not  be correlated with histopathologic findings. 
Non-neoplastic microscopic changes associated with t reatment  occurred 
only in rats. Correlation of light and electron microscopic findings indicated 
that  increased cytoplasmic eosinophilia of  hepatocytes  in animals given 100 
and 40 mg/kg corresponded to areas of proliferating smooth endoplasmic 
reticulum [6] .  This histological change was dose and time related and 
reversible following cessation of  dosing. Significantly increased incidence 
of  bile duct  proliferation and/or cholangiolar cysts was observed in rats given 
100 mg/kg. No histopathologic evidence of  malignancy was noted either in 
the proliferative or cystic lesions. 
The tumor  types  identified in treated mice were similar to those in un- 
treated controls (Table III). No significant differences in mean times of  
appearance or onset were apparent (Table IV}. The most  f requent  tumor  
types were bone osteomas and leukemia prevalent in females and alveologenic 
adenocarcinomas in both  sexes. The only statistically significant variation 
(P < 0.01) in tumor  incidence was increased lung alveologenic adenocarci- 
nomas in females given 100 mg/kg (24%), in comparison with controls (10%}. 
However,  the incidence of  this commonly  occurring tumor  type  was less 
than that noted in historical controls (41/150;  27%}. 
The tumor  types in treated rats also were similar to those in controls. 
The most  common neoplasms in both sexes were hepatocellular adenomas, 
pituitary adenomas, thyroid parafollicular cell tumors, and leukemia; and 
additionally, mammary adenocarcinomas or f ibroadenomas,  and uterine 
polyps were found in females (Table III). No significant differences in mean 
time of  appearance of  tumors were observed (Table IV). The incidence of 
hepatocellular adenomas was increased in females given 100 and 40 mg/kg, 
but  no statistically significant difference was evident. High dose females 
showed a significant decrease (P < 0.01} in the incidence of  both  mammary 
f ibroadenomas and pituitary adenomas. 
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T A B L E  III  
D I S T R I B U T I O N  OF MOST F R E Q U E N T  T U M O R  TYPES IN MICE G I V E N  T I L I D I N E  
O R A L L Y  F O R  80 WEEKS A N D  IN RATS F O R  104 WEEKS 
O r g a n / t u m o r  t ype  b 'c  T r e a t m e n t  groups  a 
Males Females 
(100)  (40)  (16)  (0)  (100)  (40)  (16)  (0)  
Mice 
Bone: 
Osteoma 1 3 1 1 7 
Liver: 
Hepatocellular adenoma 2 4 3 9 0 
Hemangioma 1 0 2 0 0 
Lung: 
Alveologenic adenocarcinoma 9 9 7 15 12 c 
Mammary gland: 
adenocarcinoma 0 0 0 0 4 
Subcutaneous: 
Fibrosarcoma 1 - 1 0 0 0 
Uterus: 
Polyp . . . .  1 
Hemangioma . . . .  0 
Generalized: 
Leukemia  4 5 4 5 3 
Animals  wi th  ben ign  t u m o r s  d 'e  4 6 5 9 8 
Animals  w i t h  ma l ignan t  t u m o r s  14 18 16 2"1 18 
Animals  w i t h  t u m o r s  17 22 17 25 21 
Rats 
Liver:  
Hepatoce l lu la r  a d e n o m a  3 3 6 4 7 
M a m m a r y  gland : 
A d e n o c a r c i n o m a  0 0 0 0 6 
F i b r o a d e n o m a  0 1 1 0 6 c 
Pancreas:  
Islet  cell t u m o r  0 0 0 5 0 
P i tu i t a ry :  
A d e n o m a  7 9 9 21 8 e 
Skin:  
Pap i l loma  0 3 0 0 0 
T h y r o i d :  
Parafol l icular  cell t u m o r  2 1 0 7 1 
Ute rus :  
Polyp . . . .  4 
Genera l ized :  
Leukemia  6 7 7 6 2 
Animals  w i th  ben ign  t u m o r s  cl'e 29 20 22 45 34 
Animals  w i th  ma l ignan t  t u m o r s  12 14 9 16 13 
Animals  w i t h  t u m o r s  38 29 29 55 40 
6 2 8 
0 0 2 
0 0 0 
11 7 10 
0 2 1 
0 2 0 
3 2 3 
0 2 0 
9 11 18 
7 6 14 
19 21 32 
25 24 38 
5 1 2 
7 1 2 
11 25 29 
0 0 1 
18 15 46 
0 1 1 
2 1 7 
3 4 11 
5 2 3 
32 36 74 
12 8 17 
36 39 81 
aNumbers in parentheses indicate dose levels of drug in mg/kg/day; number of animals/- 
sex/group indicated in Table II. 
bOnly those tumor types with a frequency of greater than 4% are listed, although all 
tumors are included in the overall incidence values. 
CProbability analysis by life-table technique; P < 0.01. 
dSome animals may have more than one tumor. 
eChi-square test used for overall tumor incidence with a frequency of > 0.20; exact 
probability test used with incidence < 0.20. 
DISCUSSION 
Tilidine fumarate (Valoron) ®, a cyclohexenyldimethylamine derivative, 
is an orally administered potent analgesic, with a mode of pain relief 
through opiate mediated effects [ 14,18--21]. Although extensive literature 
exists on the many aspects of biochemical, pharmacologic a n d  behavior- 
altering actions of potent analgesics, there is a paucity of data concerning 
carcinogenic potential or long-term effects, even though these drugs have 
been widely used for many years. The principal target organ of toxicity with 
the salicylate analgesics is the liver. In rodents, liver damage is common fol- 
lowing the administration of narcotic analgesics. Hepatic enlargement and 
fatty change were observed in rats following chronic administration of 
dextro-propoxyphene [22]. Liver lipids were not significantly changed after 
acute or chronic morphine exposure [23], although subcutaneous implan- 
tation of morphine pellets resulted in lipid accumulation in mouse hepato- 
cytes and increased serum transaminase levels [24]. Subcutaneous or intra- 
ventricular injection of morphine sulfate also elevated transaminase levels 
[25]. Impaired liver function, as measured by clearance of sulfobromoph- 
thalein, was observed following subcutaneous administration of methadone 
[26]. Liver fatty change and increased serum transaminase levels were 
found in mice following single or multiple intraperitoneal injections of 
morphine, dihydromorphine or methadone [27]. Liver damage as exemplified 
by elevated serum transaminases, abnormal flocculation and turbidity tests, 
and morphologic variations, has been observed in patients addicted to heroin 
or maintained on methadone [28--32]. Hepatotoxicity in humans has been 
associated with propoxyphene [33--35]. These studies raise the question of 
whether or not opiates have direct hepatotoxic effects. Recent investigations 
suggested that narcotic analgesics are inherently hepatotoxic because of 
hepatic giutathione reduction [ 36,37 ]. 
Analysis of morphological and biochemical characteristics of the rat liver 
response to the administration of tilidine has been reported [6]. Correlation 
of light and electron microscopic findings showed that the glassy cytoplasmic 
appearance of hepatocytes corresponded to areas of enlarged cytoplasm 
containing proliferated smooth endoplasmic reticulum (SER). Evidence of 
SER membrane proliferation together with elevated microsomal enzyme 
activity, and increased phospholipid and protein synthesis, indicated major 
enzyme induction. Accompanying these cytoplasmic changes was some 
degree of fatty change. The withdrawal segment of these studies showed that 
the proliferating and stimulating action of tilidine was reversible. There were 
no deletereous effects on hepatic subcellular structure or function in animals 
sacrificed following withdrawal from drug. 
Data reported herein from rodent carcinogenesis bioassays with the narcotic 
analgesic tilidine provide further information concerning this class of com- 
pounds. Biochemical, hematological and urinalysis parameters indicative of 
liver and kidney function were not altered in animals given tilidine chronically. 
Following the final evaluation of the- tumor response, the neoplastic lesions 
160 
included tumors commonly  observed in both sexes of  mice, such as osteomas, 
generalized lymphoid tumors, and alveologenic tumors. Rats showed more 
mammary gland and pituitary tumors than mice. Increased susceptibility to 
tumor development was not demonstrated following 80 and 104 weeks of  
tilidine administration in mice and rats, respectively. The analysis of  tumor 
data indicated: (a) lack of dose-relationship for overall tumor incidences; (b) 
lack of  dose-related increases in single tumor-type incidences; (c) lack of  
changes in onset and latency; and (d) absence of unusual or unexpected 
tumors. From these data, it was concluded that the synthetic analgesic 
tilidine does not possess tumorigenic potential in rodents. 
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